LRRC4 and ovarian carcinoma: At the mechanistic level, we showed that LRRC4 binds to the c-SH2 domain of PIK3R1 to inhibit the activity of PIK3R1 and subsequently disrupts E-cadherin-dependent collective invasion of ovarian cancer cells mediated by the PIK3R1 signaling pathway.